BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22223377)

  • 1. Synthesis, dihydrofolate reductase inhibition, anti-proliferative testing, and saturation transfer difference ¹H-NMR study of some new 2-substituted-4,6-diaminopyrimidine derivatives.
    Mohebbi S; Falcón-Pérez JM; González E; Millet O; Mato JM; Kobarfard F
    Chem Pharm Bull (Tokyo); 2012; 60(1):70-8. PubMed ID: 22223377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel 6-substituted pyrrolo [3,2-d] pyrimidine analogues as antifolate antitumor agents.
    Tian C; Wang M; Han Z; Fang F; Zhang Z; Wang X; Liu J
    Eur J Med Chem; 2017 Sep; 138():630-643. PubMed ID: 28711701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
    Ng HL; Chen S; Chew EH; Chui WK
    Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
    Gangjee A; Yu J; McGuire JJ; Cody V; Galitsky N; Kisliuk RL; Queener SF
    J Med Chem; 2000 Oct; 43(21):3837-51. PubMed ID: 11052789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrofolate reductase inhibition effect of 5-substituted pyrido[2,3-d]pyrimidines: Synthesis, antitumor activity and molecular modeling study.
    Abdelaziz OA; El Husseiny WM; Selim KB; Eisa HM
    Bioorg Chem; 2019 Sep; 90():103076. PubMed ID: 31260878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
    Gao T; Zhang C; Shi X; Guo R; Zhang K; Gu J; Li L; Li S; Zheng Q; Cui M; Cui M; Gao X; Liu Y; Wang L
    Eur J Med Chem; 2019 Sep; 178():329-340. PubMed ID: 31200235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge.
    Li H; Fang F; Liu Y; Xue L; Wang M; Guo Y; Wang X; Tian C; Liu J; Zhang Z
    Bioorg Med Chem; 2018 May; 26(9):2674-2685. PubMed ID: 29691154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
    Richardson ML; Croughton KA; Matthews CS; Stevens MF
    J Med Chem; 2004 Jul; 47(16):4105-8. PubMed ID: 15267250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
    Singh P; Kaur M; Sachdeva S
    J Med Chem; 2012 Jul; 55(14):6381-90. PubMed ID: 22734697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase.
    Wang M; Yang J; Yuan M; Xue L; Li H; Tian C; Wang X; Liu J; Zhang Z
    Eur J Med Chem; 2017 Mar; 128():88-97. PubMed ID: 28152430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel folate-hydroxamate based antimetabolites: synthesis and biological evaluation.
    Carrasco MP; Enyedy EA; Krupenko NI; Krupenko SA; Nuti E; Tuccinardi T; Santamaria S; Rossello A; Martinelli A; Santos MA
    Med Chem; 2011 Jul; 7(4):265-74. PubMed ID: 21568878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs.
    Al-Rashood ST; Aboldahab IA; Nagi MN; Abouzeid LA; Abdel-Aziz AA; Abdel-Hamide SG; Youssef KM; Al-Obaid AM; El-Subbagh HI
    Bioorg Med Chem; 2006 Dec; 14(24):8608-21. PubMed ID: 16971132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives as dihydrofolate inhibitor: design, synthesis and antifolate activity.
    Zhang Z; Wu J; Ran F; Guo Y; Tian R; Zhou S; Wang X; Liu Z; Zhang L; Cui J; Liu J
    Eur J Med Chem; 2009 Feb; 44(2):764-71. PubMed ID: 18555562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
    Gangjee A; Li W; Kisliuk RL; Cody V; Pace J; Piraino J; Makin J
    J Med Chem; 2009 Aug; 52(15):4892-902. PubMed ID: 19719239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of N-[4-[1-ethyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid as an antifolate.
    Gangjee A; Zeng Y; McGuire JJ; Kisliuk RL
    J Med Chem; 2002 Apr; 45(9):1942-8. PubMed ID: 11960504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and as potential antitumor agents.
    Gangjee A; Yu J; Kisliuk RL; Haile WH; Sobrero G; McGuire JJ
    J Med Chem; 2003 Feb; 46(4):591-600. PubMed ID: 12570380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.